The role of Hepatitis C Virus in hepatocarcinogenesis

Similar documents
Hepatitis C in Australia:

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

Hepatitis C wi w t i h Ju J dy y W y W a y t a t t

Hepatocellular Carcinoma (HCC): Burden of Disease

Metabolic Syndrome and HCC. Jacob George

Tumor incidence varies significantly, depending on geographical location.

Global Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme

Microarray Analysis and Liver Diseases

An Update HBV Treatment

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Steatosi epatica ed HCV

Hepatitis C. Core slides

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Media centre. WHO Hepatitis B. Key facts. 1 of :12 AM.

Hepatocellular Carcinoma (HCC)

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:

Epidemiology of HCV infection among HD pts in Iran and prevention strategies

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

Cancers due to 5 infections correspond to 18.6% of total cancer incidence

Detection and Characterization of Hepatocellular Carcinoma by Imaging

NASH Bench to Bedside

Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )

Viral hepatitis and Hepatocellular Carcinoma

NATURAL HISTORY OF HEPATITIS B

Autoimmune Hepatitis Events Easl

Hepatitis C in Disclosures

Envelope e_ :------, Envelope glycoproteins e_ ~ Single-stranded RNA ----, Nucleocapsid

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

Hepatitis B Virus infection: virology

Liver Cancer Causes, Risk Factors, and Prevention

Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression

Apoptosis in chronic hepatitis C

Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

FOR REVIEW. BMB Reports - Manuscript Submission. Manuscript Draft. Manuscript Number: BMB

JMSCR Volume 03 Issue 01 Page January 2015

What is Liver Cancer? About the Liver

The Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease. Ekihiro Seki, M.D.,Ph.D. University of California San Diego

White Nights of Hepatology 2016

Hepatitis C Management and Treatment

Alcoholic hepatitis is a drug-induced disorder

STOP Hepatocellular Carcinoma

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

of TERT, MLL4, CCNE1, SENP5, and ROCK1 on tumor development were discussed.

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

Expression of NS4 HCV in liver cells of HIV/HCV co-infected patients

This is a free sample of content from The Hepatitis B and Delta Viruses. Click here for more information on how to buy the book.

University of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba

-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual

The role of cytokines in hepatocellular carcinoma

PROGRAMME AT A GLANCE

Hepatitis C Resistance Associated Variants (RAVs)

HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS

Liver Pathology in the 0bese

M30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH

Spring 2017 Health & Wellness Seminar Series. Seminar 1: April 25 th, 2017

The Changing World of Hepatitis C

Molecular signature for management of hepatocellular carcinoma

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018

VIRUSES AND CANCER Michael Lea

VIRAL AND AUTOIMMUNE HEPATITIS WHAT IS HEPATITIS?

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

Update on HIV-HCV Epidemiology and Natural History

Hepatocellular carcinoma

CD133 induced tumorigenicity mice express TGF-beta receptor type II (TBRII) and embryonic liver fodrin (ELF) along with stem cell markers

Worldwide Causes of HCC

Maviret (Glecaprevir / Pibrentasvir)

: TP6.3 g dl, Alb4.3 g dl, GOT17 IU l, GPT26 IU l,

Epidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur

Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London

Hepatitis delta: often forgotten?

HBV : Structure. HBx protein Transcription activator

1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples. Major Principles:

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

Diseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic

The Alphabet Soup of Viral Hepatitis Testing

Antiviral agents in HCV

Hepatitis C Virus and Cytokine Responses

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.

Management of HepatoCellular Carcinoma

Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey

Improving Access to Quality Medical Care Webinar Series

Carcinogenesis. Carcinogenesis. 1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples

Harvoni: solution to HCV

AASLD, Boston, USA, 10 th November 2014 [oral presentation]

Journal of American Science, 2012;8(4)

Tenofovir disoproxil STADA 245 mg film-coated tablets , Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

/Webpages/zhang/chinese-full full- program.htm

Transcription:

The role of Hepatitis C Virus in hepatocarcinogenesis Laura Beretta Fred Hutchinson Cancer Research Center l8 Incidence and mortality of the five most common cancers worldwide, 2000 Incidence Lung Breast Colon Stomach Liver Mortality Lung Stomach Liver 1

Slide 2 l8 600,000 new cases per year lberetta, 3/31/2008

Variations in the mortality rates of HCC (the rates are reported per 100,000 persons) El-Serag and Rudolph, Gastroenterology 2007 Risk Factors for HCC Worldwide, by area, 2000 l1 20% 15% 20% 50-60% 60-70% 70% 70% 10-20% Hepatitis B Virus Hepatitis C Virus Persistent HBV or HCV infection account for over 80% of HCC cases 2

Slide 4 l1 the causative agents of HCC are quite well established. lberetta, 3/28/2008

Trends in US Cancer Mortality Rates Liver cancer has the fastest growing death rate in the US El-Serag and Rudolph, Gastroenterology 2007 Trends in the age distribution of HCC in the US El-Serag and Rudolph, Gastroenterology 2007 3

Hepatitis C Virus-associated Hepatocellular Carcinoma Effective population of HCV Adjusted incidence rate per 100,000 Japan USA 21.4 7.2 Estimated Incidence of Acute HCV Infection United States, 1960-2001 New Infections/100,000 140 120 100 80 60 40 20 0 Anti-HCV test (1 st generation) licensed Decline in transfusion recipients Decline in injection drug users 1960 1965 1970 1975 1980 1985 1989 1992 1995 1998 2001 Year Source: Hepatology 2000;31:777-82; Hepatology 1997;26:62S-65S; CDC, unpublished data 4

Hepatitis C estimated prevalence WHO Region Total Population (Millions) Hepatitis C prevalence Rate % Infected Population (Millions) Africa 602 5.3 31.9 Americas 785 1.7 13.1 Eastern Mediterranean 466 4.6 21.3 Europe 858 1.03 8.9 South-East Asia 1 500 2.15 32.3 Western Pacific 1 600 3.9 62.2 Total 5 811 3.1 169.7 5

l3 The connection between virus and cancer l5 Natural History of HCV Infection 3%-8% / year HCV chronic infection Noncirrhotic HCV individuals: <0.1%/year Cirrhotic patients: 3%-8%/year 6

Slide 11 l3 it remains a challenge to provide a clear and consistent pictire of the connection between virus and cancer whether the virus plays a direct or indirect role lberetta, 3/30/2008 Slide 12 l5 regional difference lberetta, 3/31/2008

Association with co-factors Environmental or genetic background underlying the incidence of HCC development reported in Japanese and Western HCV cohorts Excessive alcohol consumption HBV co-infection Overweight, Diabetes, Insulin resistance Hepatic steatosis which involves an accumulation of intracytoplasmic lipid droplets l4 Indirect involvement of the virus in HCC Chronic hepatic inflammation and cirrhosis are thought to play an important role in tumor initiation : necrosis and regeneration enhance mutagenesis in host cells, the accumulation of which culminates in HCC. 7

Slide 14 l4 extremely rare occurence of HCC in patients with autoimmune hepatitis in whom severe inflammation in the liver persists indefinitely absence of a complete set of genetic and epigenetic aberrations required for carcinogenesis. HCV induces genome instability lberetta, 3/31/2008

l6 Hepatitis C Virus Enveloped, single-stranded, positive-sense RNA virus l2 Mice with transgenic expression of viral proteins (summary of 18 models) Core protein: Development of steatosis and HCC later in life Inhibition of microsomal triglyceride transfer protein activity which is essential for hepatic lipoprotein assembly and secretion Increase the concentration of monosaturated fatty acids Activation of RXR-alpha and PPAR-alpha Induction of Insulin resistance Synergy of HCV core and alcohol in inducing oxidative stress Structural proteins Core-E1-E2: Similar results E1-E2, E2, NS3-NS4A or NS5A: No major histological changes to the liver Moriya et al J Gen Virol 1997; Moriya et al Nat Med 1998; Moriya et al Cancer Res 2001; Perlemuter et al FASEB J 2002; Lerat et al Gastroenterology 2002; Tsutsumi et al Hepatology 2002; Shintani et al Gastroenterology 2004 8

Slide 15 l2 l6 its genome consists of one large open reading frame that is initially translated into one single polyprotein and subsequently cleaved into the functional protein. lberetta, 3/28/2008 18 transgenic mouse line lberetta, 3/31/2008

l7 Relevance - Recent reports on HCV patients Chronic hepatitis C can result in fatty changes in the liver and hepatic steatosis is associated with increased frequency of HCC. Correlation between HCV infection and insulin resistance Involvement of the liver microsomal triglyceride transfer protein in HCV induced liver steatosis Increased core genetic variability in tumors compared to adjacent cirrhotic liver, supporting the importance of core genetic variability in hepatocellular carcinogenesis. HCV core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway. Mirandola et al Gastroenterology 2006, Sobesky et al Hepatology 2007, Pavio et al Oncogene 2005 These studies strongly support a direct role for core protein in liver pathogenesis. Core may predispose subjects to HCC development through its contribution to the onset of steatosis and insulin resistance. 9

Slide 17 l7 l9 even if we consider the variability of morphopgical observations and the diversoity of biochemical data lberetta, 3/31/2008 these data are particularly relevant considering recent reports on HCV patients lberetta, 3/31/2008

Recent development of cell culture models of HCV infection and replication Protein changes upon HCV replication Petra Mannova Romain Parent Sufen Shang Neha Lohia 10

HCV Infection of Huh7.5 cells P1 P3 P5 P12 P19 P27 Transcriptomic Proteomic Fold Change 8 4 2-1:1-2 -4-8 P1 P3 P5 P12 P19 P27 P1 P3 P5 P12 P19 P27 Activation of RXRA and PPARA 11

Activation of the PI3K/Akt/mTOR pathway Activation of PI3K Activation of mtor Mannova et al J Virol 2005 Mannova et al MCP 2006 N-Ras/PI3K/Akt/mTOR pathway and HCV replication Increased N-Ras levels in sub-cellular sites of HCV replication and stimulation of the PI3K-Akt-mTOR pathway by HCV contribute to the maintenance of steady-state levels of HCV replication. 12

PI3K/Akt Oncogenic pathway frequently activated in HCV-associated HCC Normal liver PTEN Tumor mtor S6 kinase Sahin et al Clin Cancer Res 2004 The PI3K/Akt/mTOR pathway and liver progenitor cells Liver progenitor cells may be important in carcinogenesis resulting from chronic liver diseases. These cells may function as tumor progenitors. Romain Parent 13

The human bipotent liver progenitor HepaRG cell line Established from the peritumoral region of an HCV-induced Edmondson grade I HCC Share several markers with the regenerative neoductules of the same area studied by IHC Share some features with liver progenitor cells HES CK19 HES CK18 M2-PK OV1 Parent et al Gastroenterology 2004 Progressively acquire a polarized hepatocytic phenotype Day 2 Day 15 B H B Day 4 Day 42 H B H 14

Cell cycle A Cell death Translational control plays a prominent role in the hepatocytic differentiation of HepaRG liver progenitor cells Innate Immunity B C D Lipid metabolism + Drug metabolism E F G Cell morphology Cell environment and Cell movement Parent and Beretta Genome Biology 2008 H I J Over-expression of an activated mtor mutant (ΔTOR) lacking the R (repressor) domain 15

Impaired hepatocytic differentiation in ΔTOR-expressing HepaRG cells Parent et al Cancer Res 2007 Reversion by rapamycin of the altered phenotype Parent et al Cancer Res 2007 16

Loss of responsiveness to TGF-β in ΔTOR-expressing HepaRG cells Cell cycle Activated mtor specifically targets: A Cell death Innate Immunity Cell death-related network: TNF superfamily members, interferons and caspases B C D Lipid metabolism + Drug metabolism Lipid homeostasis-related network PPARA, PPARD, RXRA and RXRB E F G Cell morphology Cell environment and Cell movement H I J Parent et al Cancer Res 2007 Parent and Beretta Genome Biology 2008 17

Nude mice transplanted with Δ TOR cells expressing Firefly Luciferase week 2 Liver specific PTEN knock-out results in HCC in mice Derek Masse Garrett Booth Horie et al J Clin Invest 2004 18

Collection of liver tissue at 3-months intervals Wild type 6 months PTEN mutant 6 months 9 months A B C D E F Hepatomegaly and liver steatosis A Liver weight (g) 12 10 8 6 4 2 Control Experimental p < 0.001 p < 0.001 p < 0.001 B Liver weight (g) 16 14 12 10 8 6 4 2 0 3 months 6 months 9 months 0 596C 597C 655C 660C 680C 595E 620E 622E 627E 636E 1054E 594C 683C 584C 962C 581E 643E 652E 650E 585E 590E 964E 982E 984E 1017E 1018E 1019E 1020E 1023E 342C 461C 486C 855C 864C 902C 341E 375E 458E 467E 480E 482E 688E 827E 828E 833E 858E 903E 907E 912E Controls PTEN -/- Controls PTEN -/- Controls PTEN -/- 3 months 6 months 9 months A Oil Red 0 Staining (pixels) 900000 800000 700000 600000 500000 400000 300000 200000 100000 0 3 months 6 months 9 months B Oil Red 0 Staining (pixels) 1400000 1200000 1000000 800000 600000 400000 200000 0 595E 620E 622E 627E 636E 1054E 581E 585E 590E 643E 650E 652E 964E 982E 984E 1017E 1018E 1019E 1020E 1023E 341E 375E 458E 467E 480E 482E 688E 827E 828E 833E 858E 903E 907E 912E 3 months 6 months 9 months 19

US/Histology Show Early HCC at 9 months All mice develop tumors by 12 months l10 Natural History of HCV Infection 3%-8% / year Cellular metabolic disturbances 20

Slide 40 l10 an increasing body of evidence suggest a direct involvement in cellular metabolic disturbance lberetta, 4/1/2008